Mizoram
2,927 People Diagnosed With TB In Mizoram
TB Cases in Mizoram
Aizawl: Tuberculosis Cases in Mizoram
More than 2,900 people have been diagnosed with tuberculosis (TB) in Mizoram in 2019, a Health department official said on Sunday.
Read Also: Centre to launch campaign to eradicate tuberculosis by 2025: Sitharaman
The official said that as many as 17,171 blood samples were tested out of which 2,927 were found suffering from tuberculosis.
Ninety-three per cent of the patients have been successfully treated, he said.
Of the 2,927 cases, 38 were detected in private hospitals, while 12 people were diagnosed during a drive conducted by the Health department in jails and several rehabilitation centres, he added.
Read Also: TB diagnosed as Lung Cancer: Diagnostic firm told to pay Rs 2 lakh compensation
At least 109 people were also diagnosed with multi-drug-resistant tuberculosis (MDR-TB) during the same period.
In 2018, of the 4,115 blood samples that have been tested, 2,499 people were diagnosed with TB and out of this 92 per cent were successfully cured, the official added.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!